Correlation between left ventricular filling type and geometry modality and functional change of left ventricle in patients with hypertension

Abstract

Abstract: AIM: To investigate the correlation between the left ventricular filling type and geometry modality and functional change of the left ventricle in patients with hypertension.METHODS: Systolic function indexes (FS and EF) and diastolic function indexes (E, A, EAT, EDT, E A, IVRT) in 120 patients with hypertension were measured by two dimensional ultrasonography (2-DUS) and M-mode and Doppler ultrasound.RESULTS: A rate of 83.5% in patients with hypertension appeared assured plump and configuration changes of left ventricle, and a rate of 84%in patients with hypertension appeared abnormal left ventricular filling function.The morphologic indexes were significantly different clearly in different left ventricular filling types, and the filling indexes were also significantly different in diferent left ventricular shapes.CONCLUSION: IVRT is a more important index than other factors to decide the left ventricular filling function.LVMI plays more important role than other factors in the left ventricular filling function.

Key words: echocardiography, hypertension, left ventricular filling type, geometry modality of the left ventricleconfiguration

CLC Number:

R454.3

CAI Ping, YANG Shi-kang. Correlation between left ventricular filling type and geometry modality and functional change of left ventricle in patients with hypertension[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2005, 10(8): 894-897.

References

1 中国高血压防治指南修订委员会.中国高血压防治指南[J].中华心血管病杂志, 2004;32:1060-3
2 刘国杖, 党爱民.高血压左心室肥厚的发生机制, 诊断及治疗[J].中国循环杂志, 1998;13:3
3 Roman MJ, Pickering TG, Schwartz JE, Pini R, Devereux RB. Association of carotid atherosclerosis and left ventricular hypertrophy[J].J Am Coll Cardiol, 1995;25:83-90
4 Ganau A, devereux RB, Roman MJ, Simone GD, Pickering TG, Saba PS, et al.Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension[J].J Am Coll Cardiol, 1992;19:1550-8
5 Nishimura RA, Appleton CP, Redfield MM, Ilstrup DM, Holmes DR, Tajik AJ.Noninvasive Doppler echocardiographic evaluation of left ventricular filling pressure in patients with cardiomyopathies: a simultaneous Doppler echocardiographic and cardiac catheterization study[J].J Am Coll Cardiol, 1996;28: 1226-33
6 Appleton CP, Hatla LK, Popp RL.Relation of transmitrial flow velocity patterns to left ventricular diastolic function:new insights from a combined hemodynamic and Doppler echocardiographic study[J].J Am Coll Cardiol, 1988;12:426-40
7 Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Battistelli M, Bartoccini C, et al.Adverse prognostic significance of concentric remodeling of the left ventricle in hypertensive patients with normal left ventricular mass[J].J Am Coll Cardiol, 1995;25: 871-8
8 Rossvol O, Hatla LK.Pulmonary venous flow velocities recorded by Doppler ultrasound:Relation to left ventricular diastolic pressures[J].J Am Coll Cardiol, 1993;21:1687-96
9 Li L, Shigematsu Y, Hamada M, Hiwada K.Relative wall thickness is an independent predictor of left ventricular systolic and diastolic dysfunctions in essential hypertension[J].Hypertens Res, 2001;24:493-9
10 Plothick GD.Changes in diastolic function--difficult to measure, harder to interpret[J].Am Heart J 1989;118:637
11 Erbel R, Neumann T, Zeidan Z, Bartel T, Buck T.Echocardiography diagnosis of diastolic heart failure[J].Herz, 2002;27:99-106
12 Sekuri C, Kurhan Z, Tavli T, Bayturan O, Utuk O, Bilge AR, et al.Doppler index of myocardial performance and its relationship with mitral E wave deceleration time in acute Q-wave myocardial infarction[J].Anadolu Kardiyol Derg, 2004;4:108-13
13 Wachtell K, Smith G, Gerdts E, Dahlof B, Nieminen MS, Papademetriou V, et al.Left ventricular filling patterns in patients with systemic hypertension and left ventricular hypertrophy (the LIFE study).Losartan Intervention For Endpoint[J].Am J Cardiol, 2000;85:466-72
14 LinM, Sumimoto T, Hiwada K.Left ventricular geometry and cardiac function in mild to moderate essential hypertension[J]. Hypertens Res, 1995;18:151-7
15 李虹, 单光华, 徐宏贵.老年高血压病患者的左心功能损害[J].暨南大学学报, 2001;22:93-4

[1]	NING Sisi, ZHAO Yuhong, YAN Lei, TANG Minna, ZHANG Ningzhi, ZHANG Yongqiao, CUI Zhaoqiang. Controversies over the targets of controlling blood pressure in hyper- tensive patients with chronic kidney disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 463-467.
[2]	SHEN Chang, AI Kelong, HU Changping. Research progress in the regulation of hypoxic pulmonary hypertension by hypoxia-inducible factor-1 signaling pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 114-120.
[3]	FU Hong, TIAN Lei. Individualized precision therapy for patients with ischemic stroke and hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 870-876.
[4]	CHEN Wengang, YIN Qin, ZHANG Weiwei, ZHOU Lulu, KOU Wanqing, YUAN Xiaolong. Distributions of MTHFR gene polymorphism and its correlation with blood Hcy in patients with hypertension in southern Anhui province [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 768-774.
[5]	ZHANG Ningzhi, ZHAO Yuhong, TANG Minna, ZHANG Yongqiao, NING Sisi, CUI Zhaoqiang. Application of chronopharmacology in the hypertension treatment [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 418-422.
[6]	CUI Sumei, CUI Zhaoqiang. Application of β-blockers for hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 423-427.
[7]	LI Yuanfang, CUI Zhaoqiang. Treatment of hypertension complicated with hyperuricemia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 428-432.
[8]	XU Jianfei, LIN Li. Research progress in pharmacological and non-pharmacological treatments of hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 433-441.
[9]	KUAI Zheng, ZHANG Xiaoyi, ZOU Yunzeng. Angiotensin receptor neprilysin inhibitor in elderly with hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 442-445.
[10]	LIU Guijian, CHENG Kuan, ZHU Wenqing, GE Junbo. Progress of hypertension pharmacological treatment [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 446-449.
[11]	MENG Shi, WANG Zhongqun. Research progress on human immunodeficiency virus-associated pulmonary arterial hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(12): 1431-1440.
[12]	WANG Rui, PAN Jinjin, LI Hua, YUAN Yuhui. Research progress of melatonin on pulmonary hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 444-448.
[13]	XING Kai, GONG Jinyu, LUO Jianquan. Advances on pharmacogenomics of diuretics-related adverse reactions [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(2): 204-212.
[14]	YE Peng, TAN Xing, LENG Yueqi, WANG Yangkai, WANG Weizhong. Current opinions and developments of non-pharmacological treatments of hypertension based on sympathetic nervous system [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(12): 1335-1343.
[15]	HU Xiaoyan, XU Qiuping. Application of levosimendan in severe patients after cardiac surgery [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(9): 1027-1032.